Gilotrif FDA Approval History
FDA Approved: Yes (First approved July 12, 2013)
Brand name: Gilotrif
Generic name: afatinib
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Development timeline for Gilotrif
|Jan 16, 2018||Approval FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC|
|Apr 15, 2016||Approval FDA Approves Gilotrif (afatinib) for Patients with Squamous Cell Carcinoma of the Lung|
|Jul 12, 2013||Approval FDA Approves Gilotrif for Late Stage Non-Small Cell Lung Cancer|
|Jan 15, 2013||U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.